{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:15:28Z","timestamp":1791515728637,"version":"4.3.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) remains incurable despite effective therapies, with most patients eventually relapsing. Chimeric antigen receptor (CAR) T-cell therapy has improved treatment options but is limited by antigen escape and lack of durable responses. To expand the spectrum of actionable antigens, we sought to identify novel CAR-T actionable targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 11 publicly available single-cell RNA sequencing datasets from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), MM, relapsed\/refractory MM (RRMM) and healthy donors. Plasma cell\u2013specific surface proteins were identified via bioinformatic filtering and validated on external bulk transcriptomic database of ~2,000 patients and by flow cytometry on MM cell lines and primary bone marrow samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 15 plasma cell\u2013associated surface proteins, including BCMA, CD138, CD38, and SLAMF7. Five molecules\u2014TNFRSF13B (TACI), CD59, FCGR2B (CD32B), SLC44A1 (CD92), and CD320\u2014were prioritized for further study. CD320 and SLC44A1 were upregulated with disease stage and associated with poor survival, while TNFRSF13B, CD59, and FCGR2B were enriched in advanced disease and linked to better outcomes. Cytogenetic clustering linked these molecules to specific genetic backgrounds, suggesting subtyperelated expression patterns. Flow cytometry confirmed the surface expression of CD59, SLC44A1, TNFRSF13B and CD320.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1737919","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:26Z","timestamp":1768286126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Francesca","family":"Garofano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Corsale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Biondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Gull\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR T-cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref4","first-page":"564","article-title":"The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease","volume":"16","author":"Gandolfi","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/cells13100853","article-title":"Multiple myeloma: the role of autologous stem cell transplantation in the era of immunotherapy","volume":"13","author":"Rocchi","year":"2024","journal-title":"Cells"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jtct.2022.06.013","article-title":"High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma","volume":"28","author":"O Ali","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u0393-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1002\/ajh.26750","article-title":"Antibody drug conjugates for the treatment of multiple myeloma","volume":"98","author":"Leong","year":"2023","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/jha2.729","article-title":"T-cell redirecting bispecific antibodies in multiple myeloma: current landscape and future directions","volume":"4","author":"O'Neill","year":"2023","journal-title":"EJHaem"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.blre.2024.101242","article-title":"From MGUS to multiple myeloma: unraveling the unknown of precursor states","volume":"68","author":"Hevroni","year":"2024","journal-title":"Blood Rev"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"104268","DOI":"10.1016\/j.lpm.2025.104268","article-title":"Updates on mechanisms of disease progression in precursor myeloma: monoclonal gammopathy of undermined significance and smoldering myeloma","volume":"54","author":"Saade","year":"2025","journal-title":"Presse Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3390\/cancers17040653","article-title":"Multiple myeloma insights from single-cell analysis: clonal evolution, the microenvironment, therapy evasion, and clinical implications","volume":"17","author":"Li","year":"2025","journal-title":"Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.3390\/ijms20051248","article-title":"The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"101925","DOI":"10.1016\/j.xcrm.2024.101925","article-title":"Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets","volume":"6","author":"Rueda","year":"2025","journal-title":"Cell Rep Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"104560","DOI":"10.1016\/j.critrevonc.2024.104560","article-title":"A systematic literature review on clonal evolution events preceding relapse in multiple myeloma","volume":"205","author":"Zimmer Jakobsen","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2023","journal-title":"Am J Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/ejh.14051","article-title":"Car T cell therapy in multiple myeloma, where are we now and where are we heading for?","volume":"112","author":"Fischer","year":"2024","journal-title":"Eur J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.2217\/fon-2022-1317","article-title":"Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Martin","year":"2023","journal-title":"Future Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17474086.2024.2370552","article-title":"T-cell exhaustion in multiple myeloma","volume":"17","author":"\u017by\u0142ka","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1182\/blood.2022017145","article-title":"Single-cell profiling in multiple myeloma: insights, problems, and promises","volume":"142","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","article-title":"Single-cell profiling of tumour evolution in multiple myeloma\u2014opportunities for precision medicine","volume":"19","author":"Dutta","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"101362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"der Van Schans","year":"2020","journal-title":"Front Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41375-018-0242-6","article-title":"APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications","volume":"33","author":"Tai","year":"2019","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1038\/s41467-023-43416-7","article-title":"Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma","volume":"14","author":"Larson","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1737919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:28Z","timestamp":1768286128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1737919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":42,"alternative-id":["10.3389\/fmed.2025.1737919"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1737919","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1737919"}}